Search Results - "O'Dea, Declan"

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib by Wander, Seth A, O'Brien, Neil, Litchfield, Lacey M, O'Dea, Declan, Morato Guimaraes, Claudia, Slamon, Dennis J, Goel, Shom

“…Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive…”
Get full text

Recent advances in the vibrational spectroscopic diagnosis of non-small cell lung cancer by O’Dea, Declan, Lyng, Fiona M., Nicholson, Siobhan, O'Connell, Finbar, Maguire, Aoife, Malkin, Alison

“…Lung cancer is the leading cause of cancer deaths worldwide accounting for 1.69 million deaths in 2015. Studies have indicated a 5 year survival rate of 8%–15%…”
Get full text

Raman spectroscopy for the preoperative diagnosis of thyroid cancer and its subtypes: An in vitro proof‐of‐concept study by O'Dea, Declan, Bongiovanni, Massimo, Sykiotis, Gerasimos P., Ziros, Panos G., Meade, Aidan D., Lyng, Fiona M., Malkin, Alison

“…Objective In 2016, there were an estimated 56 870 new cases of thyroid cancer (TC) in the USA. Fine needle aspiration cytology (FNAC) is the most safe,…”
Get full text

Raman spectral cytopathology for cancer diagnostic applications by Traynor, Damien, Behl, Isha, O’Dea, Declan, Bonnier, Franck, Nicholson, Siobhan, O’Connell, Finbar, Maguire, Aoife, Flint, Stephen, Galvin, Sheila, Healy, Claire M., Martin, Cara M., O’Leary, John J., Malkin, Alison, Byrne, Hugh J., Lyng, Fiona M.

“…Raman spectroscopy can provide a rapid, label-free, nondestructive measurement of the chemical fingerprint of a sample and has shown potential for cancer…”
Get full text

Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm by Ni, Lan, Khan, Azhar Zaman, Long, Amanda, Gao, Ling, Toms, Nikki, Gonzalez‐Gugel, Elena, Holsmer‐Brand, Susan, Lin, Yong, Abada, Paolo, Dickin, Sandra, O'Dea, Declan, Wei, Ran, Jen, Min‐Hua, Aggarwal, Himani

“…Model‐informed drug development (MIDD) is a process that integrates drug exposure‐based, biological, and statistical models to enhance the benefit–risk balance…”
Get full text